Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Industry performance is calculated based on the previous closing price of all industry constituents
Largest Companies in This Industry
View MoreName | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
|---|---|---|---|---|---|---|---|
| | 140.41 | 26.41% | | | | Buy | |
| | 116.12 | 17.56% | | | | Strong Buy | |
| | 424.25 | 16.64% | | | | Buy | |
| | 97.10 | 12.12% | | | | Buy | |
| | 80.30 | 5.03% | | | | Buy | |
| | 97.68 | 3.70% | | | | Strong Buy | |
| | 250.11 | 2.52% | | | | Buy | |
| | 109.16 | 2.13% | | | | Hold | |
| | 313.60 | 2.11% | | | | Buy | |
| | 318.59 | 1.26% | | | | Buy |
Investing in the Medical Devices Industry
Start Investing in Medical Devices Through These Companies
Top Performing Companies
View MoreName | Last Price | 1Y Target Est. | YTD Return |
|---|---|---|---|
| | - | | |
| | - | | |
| | 5.50 | | |
| | 6.73 | | |
| | 15.00 | |
High Growth Companies
View MoreName | Last Price | Growth Estimate | YTD Return |
|---|---|---|---|
| | | | |
| | | | |
| | | | |
| | | | |
| | | |
Medical Devices Research
View MoreDiscover the Latest Analyst and Technical Research for This Industry
Analyst Report: LivaNova PLC
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
RatingPrice TargetDaily – Vickers Top Insider Picks for 05/07/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
BRKR: Lowering target price to $41.00
BRUKER CORP has an Investment Rating of HOLD; a target price of $41.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetCTKB: What does Argus have to say about CTKB?
CYTEK BIOSCIENCES INC has an Investment Rating of SELL; a target price of $3.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice Target